Equity research analysts covering Protalix BioTherapeutics (NYSE: PLX) generally maintain a favorable outlook, issuing consensus buy recommendations supported by its proprietary ProCellEx plant cell-based protein expression platform and commercialized rare disease treatments like Elfabrio. Analysts emphasize potential long-term upside based on clinical pipeline execution, though investors are reminded to weigh standard developmental risks and cash flow milestones.